Genetically Engineered Malaria Vaccine Blocks Infection
Quick Facts
What is a genetically engineered malaria vaccine and how does it work?
Malaria is caused by Plasmodium parasites transmitted by Anopheles mosquitoes. The parasite first infects the liver before invading red blood cells, where it causes symptoms. Genetically attenuated parasite vaccines aim to exploit that early liver stage: parasites are engineered with specific genes deleted so they can enter liver cells and prompt a strong immune response, but cannot progress to cause blood-stage illness.
This whole-organism approach differs from the two WHO-recommended vaccines, RTS,S and R21/Matrix-M, which target a single parasite protein, the circumsporozoite protein. Exposing the immune system to many parasite antigens may produce broader and more durable T-cell and antibody responses, which is the central rationale for the strategy. Reports of the new trial say infection was prevented in 87% of volunteers, according to coverage in EurekAlert.
How should the 87% protection figure be interpreted?
First efficacy studies of malaria vaccine candidates commonly use controlled human malaria infection, in which healthy volunteers are deliberately exposed to infectious mosquito bites or parasites under close medical supervision and treated promptly. This provides a rapid read on whether a vaccine blocks infection, but participants are typically malaria-naive adults in non-endemic settings, and sample sizes are small.
Natural transmission differs: people in endemic regions face repeated exposures, diverse parasite strains, co-infections and malnutrition, and children are the most affected group. Durability, safety across age groups, manufacturing and delivery (whole-parasite vaccines often need cryopreserved formulations and sometimes intravenous administration) are practical hurdles. Larger field trials will be needed before any conclusions about public health impact.
Why does malaria still need new vaccines?
The World Health Organization reports that malaria causes several hundred thousand deaths annually, the majority among children under five in sub-Saharan Africa. WHO has recommended RTS,S/AS01 and R21/Matrix-M for children in areas of moderate to high transmission, and rollouts have begun in multiple countries. Both reduce clinical malaria but are not fully protective, and protection wanes over time, so boosters are used.
Meanwhile, challenges such as insecticide resistance in mosquitoes, parasite resistance to artemisinin-based therapies, and funding gaps threaten progress. Vaccines with higher and longer-lasting efficacy against infection could complement bed nets, seasonal chemoprevention and treatment, and potentially support elimination efforts.
Frequently Asked Questions
No. It is at an early stage of clinical testing and would need larger trials and regulatory review before any approval.
Not necessarily. Trials differ in design, population and exposure type, so direct comparisons are unreliable without head-to-head studies.
WHO recommends RTS,S/AS01 and R21/Matrix-M for children in regions with moderate to high malaria transmission.
References
- EurekAlert! Genetically engineered malaria vaccine stops infection in 87% of volunteers in first efficacy trial. November 2026.
- World Health Organization. World Malaria Report.
- World Health Organization. Malaria vaccines (RTS,S and R21) position and recommendations.